{"id":"npb-01","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited publicly available information exists regarding NPB-01's specific mechanism of action. As a phase 3 candidate from Nihon Pharmaceutical, it represents an investigational compound under active clinical evaluation, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.","oneSentence":"NPB-01 is a novel therapeutic agent in phase 3 development by Nihon Pharmaceutical Co., Ltd.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:29.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05177939","phase":"PHASE3","title":"Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis","status":"UNKNOWN","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2022-03-03","conditions":"Autoimmune Encephalitis","enrollment":40},{"nctId":"NCT02221271","phase":"PHASE3","title":"Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2014-10","conditions":"Guillain-Barré Syndrome","enrollment":22},{"nctId":"NCT01845584","phase":"PHASE2","title":"Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2013-05","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":7},{"nctId":"NCT01827072","phase":"PHASE3","title":"Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2013-04","conditions":"Multifocal Motor Neuropathy","enrollment":13},{"nctId":"NCT01824251","phase":"PHASE3","title":"Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2013-04","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":49},{"nctId":"NCT01696500","phase":"PHASE3","title":"Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2012-10","conditions":"Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis","enrollment":10},{"nctId":"NCT01408550","phase":"PHASE3","title":"Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2011-08","conditions":"Bullous Pemphigoid","enrollment":56},{"nctId":"NCT00809822","phase":"PHASE2","title":"Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2008-11","conditions":"Bullous Pemphigoid","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["immunoglobulin","Intravenous immunoglobulin"],"phase":"phase_3","status":"active","brandName":"NPB-01","genericName":"NPB-01","companyName":"Nihon Pharmaceutical Co., Ltd","companyId":"nihon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}